SWIFT: Prospective 48-week study to evaluate efficacy and safety of switching to emtricitabine/tenofovir from lamivudine/abacavir in virologically suppressed hiv-1 infected patients on a boosted protease inhibitor containing antiretroviral regimen

Clinical Infectious Diseases

Volumn 56, Issue 11, 2013, Pages 1637-1645

  Campo, R ^a   Dejesus, E ^b   Bredeek, U F ^c   Henry, K ^d   Khanlou, H ^e   Logue, K ^f   Brinson, C ^g   Benson, P ^h   Dau, L ⁱ   Wang, H ⁱ   White, K ⁱ   Flaherty, J ⁱ   Fralich, T ⁱ   Guyer, B ⁱ   Piontkowsky, D ⁱ  

^a UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

^b ORLANDO IMMUNOLOGY CENTER   (United States)

^c Metropolis Medical ^*  (United States)

^d HENNEPIN COUNTY MEDICAL CENTER   (United States)

^e Medical Institute of Immunology and Infectious Diseases   (United States)

^f St Clair Medical Associates   (Canada)

^g Central Texas Clinical Research   (United States)

^h Be Well Medical Center   (United States)

ⁱ GILEAD SCIENCES   (United States)

Author keywords

3TC ABC; FTC TDF; HIV 1; switch; virologic failure

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR PLUS RITONAVIR; CHOLESTEROL; DARUNAVIR PLUS RITONAVIR; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EPIDERMAL GROWTH FACTOR RECEPTOR; FOSAMPRENAVIR PLUS RITONAVIR; HIGH DENSITY LIPOPROTEIN; LOPINAVIR PLUS RITONAVIR; LOW DENSITY LIPOPROTEIN; PROTEINASE INHIBITOR; RITONAVIR; TRIACYLGLYCEROL; VIRUS RNA;

ADULT; AGED; ARTICLE; CD4 LYMPHOCYTE COUNT; CHOLESTEROL BLOOD LEVEL; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIARRHEA; DIZZINESS; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; FLATULENCE; FRAMINGHAM RISK SCORE; GLOMERULUS FILTRATION RATE; GLUCOSURIA; HEADACHE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOPHOSPHATEMIA; KIDNEY DISEASE; KIDNEY DYSFUNCTION; MAJOR CLINICAL STUDY; MALAISE; MALE; NAUSEA; OPEN STUDY; PHOSPHATE BLOOD LEVEL; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; RASH; SIDE EFFECT; URINE ODOR; VIREMIA;

3TC/ABC; FTC/TDF; HIV-1; SWITCH; VIROLOGIC FAILURE;

ADENINE; ADULT; AGED; ANTI-RETROVIRAL AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; BIOLOGICAL MARKERS; DEOXYCYTIDINE; DIDEOXYNUCLEOSIDES; DRUG COMBINATIONS; FEMALE; HIV INFECTIONS; HUMANS; KAPLAN-MEIER ESTIMATE; LAMIVUDINE; MALE; MIDDLE AGED; ORGANOPHOSPHONATES; PROSPECTIVE STUDIES; PROTEASE INHIBITORS; PROTEINURIA; RISK;

EID: 84877293559     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/cis1203     Document Type: Article

References (22)

1. Department of Health and Human Services (DHHS). Guidelines for the use of antiretroviral agents in HIV-1-infected adults and adolescents, 2012. Available at: http://AIDSinfo.nih.gov.
2. Martinez E, Arranz JA, Podzamczer D, et al. Efficacy and safety of NRTI's switch to tenofovir plus emtricitabine (Truvada) vs abacavir plus lamivudine (Kivexa) in patients with virologic suppression receiving a lamivudine containing HAART: The BICOMBO study [oral presentation]. Paper presented at: 4th International AIDS Society Conference on HIV Pathogenesis, Treatment, and Prevention (IAS). Sydney, Australia, July 22-26, 2007.
3. Sax PE, Tierney C, Collier AC, et al. Abacavir-lamivudine versus teno-fovir-emtricitabine for initial HIV-1 therapy. N Engl J Med 2009; 361:2230-40.
4. Valantin MA, Bittar R, de Truchis P, et al. Switching the nucleoside reverse transcriptase inhibitor backbone to tenofovir disoproxil fumarate + emtricitabine promptly improves triglycerides and low-density lipoprotein cholesterol in dyslipidaemic patients. J Antimicrob Chemother 2010; 65:556-61.
5. Behrens G, Maserati R, Rieger A, et al. Switching from kivexa [ABC/3TC]+kaletra [LPV/r] to truvada [TDF/FTC]+kaletra [LPV/r] reduces high hholesterol: results of a 12 week randomized, controlled study (ROCKET II) [Poster WEPE0110]. Poster presented at: XVIII International AIDS Conference. Vienna, Austria, July 18-23, 2010.
6. Moyle G, Orkin C, Fisher M, et al. Switching from kivexa (KVX) + efavirenz (EFV) to atripla (ATR) reduces total cholesterol in hyper-cholesterolemic subjects: final results of a 24-week, andomised study [poster P80]. Poster presented at: 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 7-11, 2010.
7. Worm SW, Sabin C, Weber R, et al. Risk of myocardial infarction in patients with HIV infection exposed to specific individual antiretrovi-ral drugs from the 3 major drug classes: the data collection on adverse events of anti-HIV drugs (D:A:D) study. J Infect Dis 2010; 201: 318-30.
8. SMART/INSIGHT and D:A:D Study Groups. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS 2008; 22:F17-24.
9. Lang S, Mary-Krause M, Cotte L, et al. Impact of individual antiretro-viral drugs on the risk of myocardial infarction in human immunodeficiency virus-infected patients: a case-control study nested within the French Hospital Database on HIV ANRS cohort CO4. Arch Intern Med 2010; 170:1228-38.
10. Durand M, Sheehy O, Baril JG, Lelorier J, Tremblay CL. Relation between use of nucleosidic reverse transcriptase inhibitors (NRTI) and risk of acute myocardial infarction (AMI): a nested case control study using Quebec's public health insurance database (RAMQ)[poster]. Paper presented at: 5th IAS Conference on HIV Pathogenesis, Treatment, and Prevention. Cape Town, South Africa, July 19-22, 2009.
11. Bedimo R, Westfall A, Drechsler H, Vidiella G, Tebas P. Abacaviruse and risk of acute myocardial infarction and cerebrovascular disease in the HAART era [oral presentation]. Paper presented at: 5th IAS Conference on HIV Pathogenesis, Treatment and Prevention. Cape Town, South Africa, July 19-22, 2009.
12. Triant VA, Regan S, Lee H, Sax PE, Meigs JB, Grinspoon SK. Association of immunologic and virologic factors with myocardial infarction rates in a US healthcare system. J Acquir Immune Defic Syndr 2010; 55:615-9.
13. Ding X, Andraca-Carrera E, Cooper C, et al. No association of abaca-vir use with myocardial infarction: findings of an FDA meta-analysis. J Acquir Immune Defic Syndr 2012; 61:441-7.
14. Thompson MA, Mugavero MJ, Amico KR, et al. Guidelines for improving entry into and retention in care and antiretroviral adherence for persons with HIV: evidence-based recommendations from an international association of physicians in AIDS care panel. Ann Intern Med 2012; 156:817-33.
15. Framingham Heart Study. A Project of the National heart, lung, and blood institute and Boston University. Available at: http://www. framinghamheartstudy. org. Accessed 3 January 2012.
16. National Cholesterol Education Program (NCEP). Third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) Executive Summary. 2001.
17. Lima V, Harrigan R, Montaner JS. Increased reporting of detectable plasma HIV-1 RNA levels at the critical threshold of 50 copies per milliliter with the TaqMan assay in comparison to the Amplicor assay. J Acquir Immune Defic Syndr 2009; 51:3-6.
18. Damond F, Roquebert B, Benard A, et al. Human immunodeficiency virus type 1 (HIV-1) plasma load discrepancies between the Roche COBAS AMPLICOR HIV-1 MONITOR Version 1.5 and the Roche COBAS AmpliPrep/COBAS TaqMan HIV-1 assays. J Clin Microbiol 2007; 45:3436-38.
19. Post FA, Moyle GJ, Stellbrink HJ, et al. Randomized comparison of renal effects, efficacy, and safety with once-daily abacavir/lamivudine versus tenofovir/emtricitabine, administered with efavirenz, in antiretroviral-naive, HIV-1-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr 2010; 55:49-57.
20. Gallant JE, Winston JA, DeJesus E, et al. The 3-year renal safety of a tenofovir disoproxil fumarate vs a thymidine analogue-containing regimen in antiretroviral-naive patients. AIDS 2008; 22:2155-63.
21. Madruga JV, Cassetti I, Etzel A, et al. The 10-year safety and efficacy of tenofovir DF (TDF)-containing HAART in antiretroviral naive patients [poster P086]. Poster presented at: 10th International Congress on Drug Therapy in HIV Infection. Glasgow, UK, November 7-11, 2010.
22. Laprise C, Baril JG, Dufresne S, Trottier H. Association between tenofovir exposure and reduced kidney function in a cohort of HIV-positive patients: results from 10 years of follow-up. Clin Infect Dis 2012.